
Thomas Han spent decades learning how medicines move from a promising idea to a durable business. At Peroxitech, he is applying that education to the hardest hand-off in biotech: turning university science into a company that can keep moving.
The Philadelphia spinout is trying to stop acute lung injury before oxidative damage snowballs. Its unusually small peptide has survived mice, pigs and a $25 million financing - but the decisive human test still lies ahead.